Log in

NASDAQ:KINKindred Biosciences Stock Price, Forecast & News

$4.70
-0.07 (-1.47 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.68
Now: $4.70
$5.01
50-Day Range
$3.63
MA: $4.61
$5.24
52-Week Range
$3.11
Now: $4.70
$11.93
Volume491,778 shs
Average Volume554,699 shs
Market Capitalization$184.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Read More
Kindred Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.72 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIN
CUSIPN/A
Phone650-701-7901

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.26 million
Book Value$2.10 per share

Profitability

Net Income$-61,390,000.00
Net Margins-1,567.56%

Miscellaneous

Employees146
Market Cap$184.66 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

How has Kindred Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Kindred Biosciences' stock was trading at $8.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KIN shares have decreased by 41.9% and is now trading at $4.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kindred Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kindred Biosciences.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Kindred Biosciences.

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.04. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analysts' expectations of $1.75 million. Kindred Biosciences had a negative net margin of 1,567.56% and a negative return on equity of 72.77%. View Kindred Biosciences' earnings history.

What price target have analysts set for KIN?

7 brokerages have issued 1-year price targets for Kindred Biosciences' stock. Their forecasts range from $8.50 to $13.00. On average, they expect Kindred Biosciences' stock price to reach $10.88 in the next twelve months. This suggests a possible upside of 131.4% from the stock's current price. View analysts' price targets for Kindred Biosciences.

Has Kindred Biosciences been receiving favorable news coverage?

News coverage about KIN stock has been trending neutral recently, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kindred Biosciences earned a news impact score of 0.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutKindred Biosciences.

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 383,500 shares, a decrease of 12.3% from the April 30th total of 437,100 shares. Based on an average daily volume of 220,200 shares, the short-interest ratio is currently 1.7 days. Approximately 1.0% of the shares of the stock are short sold. View Kindred Biosciences' Current Options Chain.

Who are some of Kindred Biosciences' key competitors?

What other stocks do shareholders of Kindred Biosciences own?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the following people:
  • Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
  • Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
  • Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.27%), Morgan Stanley (4.41%), Morgan Stanley (4.41%), Granahan Investment Management Inc. MA (2.34%), State Street Corp (1.76%) and Geode Capital Management LLC (1.37%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View institutional ownership trends for Kindred Biosciences.

Which institutional investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Parametric Portfolio Associates LLC, UBS Group AG, WINTON GROUP Ltd, Morgan Stanley, Morgan Stanley, State Street Corp, and Wells Fargo & Company MN. View insider buying and selling activity for Kindred Biosciences.

Which institutional investors are buying Kindred Biosciences stock?

KIN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Granahan Investment Management Inc. MA, Geode Capital Management LLC, Cambridge Investment Research Advisors Inc., Deutsche Bank AG, New York State Common Retirement Fund, Bank of New York Mellon Corp, and Nuveen Asset Management LLC. View insider buying and selling activity for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $4.70.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $184.66 million and generates $4.26 million in revenue each year. The biopharmaceutical company earns $-61,390,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is kindredbio.com.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.